Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Lexicon Pharmaceuticals (LXRX) Stock Price & Analysis
893 Followers
LXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.31 - $3.48
Previous Close$2.37
Volume25.41K
Average Volume (3M)400.51K
Market Cap
$446.34M
Enterprise Value$352.89M
Total Cash (Recent Filing)$138.36M
Total Debt (Recent Filing)$55.29M
Price to Earnings (P/E)-3.8
Beta1.81
Next Earnings
May 04, 2023EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding188,725,743
10 Day Avg. Volume418,998
30 Day Avg. Volume400,510
Standard Deviation0.34
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.03
Price to Sales (P/S)3149.95
Price to Cash Flow (P/CF)1.30
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.54K
Enterprise Value/Gross Profit2.54K
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$3.00Price Target Upside26.85% Upside
Rating ConsensusHold
Number of Analyst Covering1
Lexicon Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.31 and its highest was $3.48 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Currently, no data Available
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is May 04, 2023 which is in 34 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Mar 02, 2023. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.134 by -$0.026.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -$0.18.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 188,725,740 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.134. Following the earnings report the stock price went up 22.936%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Among the largest hedge funds holding Lexicon Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Lexicon Pharmaceuticals’s shares valued at 1M.
---
Lexicon Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (26.85% Upside)
$3.00 (26.85% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 106.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.71%
12-Months-Change
Fundamentals
Return on Equity
-88.37%
Trailing 12-Months
Asset Growth
41.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
---
Top 5 ETFs holding LXRX
iShares Core S&P Total U.S. Stock Market ETF
$589.60K
Schwab U.S. Broad Market ETF
$125.84K
Up to five ETFs with an Outperform Smart Score that hold LXRX. The ETFs are listed according to market value of LXRX within the ETF
---
Biohaven Ltd.
―
Atara Biotherapeutics
―
Nkarta
―
C4 Therapeutics
―
Scholar Rock Holding
―
---